Liletta is owned by Medicines360.
Liletta contains Levonorgestrel.
Liletta has a total of 2 drug patents out of which 0 drug patents have expired.
Liletta was authorised for market use on 26 February, 2015.
Liletta is available in intrauterine device;intrauterine dosage forms.
Liletta can be used as a method for prevention of pregnancy.
The generics of Liletta are possible to be released after 22 March, 2034.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11090186||MEDICINES360||Methods for using intrauterine systems and IUD insertion devices|| |
(10 years from now)
|US10028858||MEDICINES360||Intrauterine systems, IUD insertion devices, and related methods and kits therefor|| |
(11 years from now)
Market Authorisation Date: 26 February, 2015
Treatment: A method for prevention of pregnancy
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic